Study of Oral Treatments for Hepatitis C

Condition:   Chronic Hepatitis CInterventions:   Drug: sofosbuvir/ledipasvir;   Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir;   Drug: elbasvir/grazoprevirSponsors:   University of North Carolina, Chapel Hill;   Patient-Centered Outcomes Research Institute;   Merck Sharp & Dohme Corp.;   AbbVieNot yet recruiting - verified May 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

NPs should be given a more significant role in this effort.
Source: AJN - Category: Nursing Tags: Viewpoint Source Type: research
Source: Clinical and Experimental Gastroenterology - Category: Gastroenterology Tags: Clinical and Experimental Gastroenterology Source Type: research
Conclusions: The level of knowledge of HCV is suboptimal, and the self-reported testing rate for HCV is less than 10%; however, once HCV infection is diagnosed, the treatment rate seems to be high in South Korea. More active campaigns and effective screening are needed. PMID: 32066209 [PubMed - as supplied by publisher]
Source: Gut and Liver - Category: Gastroenterology Tags: Gut Liver Source Type: research
We report the median and 95% uncertainty interval (UI) from 1151 modelled runs.FindingsOne-time screening of 90% of the 2018 population by 2030, with 80% referral to treatment, was projected to lead to 13·8 million (95% UI 13·4–14·1) individuals being screened and 350 000 (315 000–385 000) treatments started annually, decreasing hepatitis C incidence by 26·5% (22·5–30·7) over 2018–30. Prioritised screening of high prevalence groups (PWID and adults aged ≥30 years) and rescreening (annually for PWID, otherwise every 10 years) are likely to increase t...
Source: The Lancet Global Health - Category: International Medicine & Public Health Source Type: research
Publication date: March 2020Source: The Lancet Global Health, Volume 8, Issue 3Author(s): Zaigham Abbas, Minaam Abbas
Source: The Lancet Global Health - Category: International Medicine & Public Health Source Type: research
A large investment of at least US$3.9 billion needed to meet the World Health Organisation ’ s (WHO) target for the elimination of Hepatitis C virus (HCV) in Pakistan could deliver huge benefits in terms of lives saved and reduced ill health, according to University of Bristol led research published in The Lancet Global Health today [19 February].
Source: University of Bristol news - Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Population Health Sciences; Press Release Source Type: news
ConclusionsThe efficacy and safety profiles observed in this study support the administration of nivolumab in mRCC patients infected with HCV and warrant further investigation.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Publication date: Available online 19 February 2020Source: Journal of Cardiology CasesAuthor(s): Chiaki Goten, Soichiro Usui, Takuto Hamaoka, Tomoya Harada, Oto Inoue, Hirofumi Okada, Shin-ichiro Takashima, Takeshi Kato, Hisayoshi Murai, Kenji Sakata, Hiroshi Furusho, Masa-aki Kawashiri, Masayuki TakamuraAbstractThe prognosis of pulmonary arterial hypertension (PAH) has significantly improved over the past two decades due to advances in medications, including pulmonary vasodilators. However, the side effects of these drugs remain problematic in some patients. A 51-year-old woman with chronic hepatitis C was diagnosed with ...
Source: Journal of Cardiology Cases - Category: Cardiology Source Type: research
For more information go tohttps://www.cc.nih.gov/about/news/grcurrent.htmlAir date: 3/4/2020 12:00:00 PM
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
We read and appreciate the report of the executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline in Kidney International.1 Direct-acting antivirals are now the standard of care for chronic hepatitis C either in the general population or in patients with chronic kidney disease. A sustained virological response rate of>95% could be achieved with novel direct-acting antivirals. We acknowledge that the statement regarding the treatment recommendations should refer to the latest American Association for the Study of Liver Diseases (AASLD) or European Association for the Study of the Liver (EASL) guidelines.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Letter to the Editor Source Type: research
More News: Hepatitis | Hepatitis C | Norvir | Research | Study